Marthe Minderman

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.

Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.

Journal: Blood advances
Published: August 24, 2023

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.

Journal: Blood cancer journal
Published: March 12, 2023

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.

Journal: Blood cancer journal
Published: January 19, 2023

Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.

Prevalence and prognostic value of MYD88 and CD79B mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.

Journal: The British journal of ophthalmology
Published: May 02, 2021

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.

Journal: Blood
Published: February 18, 2021

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma.

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma.

Journal: Haematologica
Published: October 15, 2020

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.

Journal: Leukemia
Published: February 25, 2020

Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.

Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.

Journal: Nature communications
Published: July 09, 2015
Showing 1-8 of 8

Last Updated: 09/26/2026